PTC Therapeutics | PTCT - Current Assets


PTC Therapeutics reported $2.27B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
BioCryst Pharmaceuticals USD 404.35M 48.66M Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Cytokinetics USD 916.97M 60.37M Dec/2025
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
Ironwood Pharmaceuticals USD 273.84M 82.09M Sep/2025
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
TG Therapeutics USD 630.76M 31M Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025
Xencor USD 599.82M 81.38M Dec/2025